Cardinal Health (CAH) Q3 2026 Earnings Transcript

Cardinal Health reported a strong quarter, with revenue up 11% to $61 billion, non-GAAP EPS up 35% to $3.17, gross profit up 18%, and operating earnings up 18%. Management raised full-year non-GAAP EPS guidance to $10.70-$10.80 and adjusted free cash flow guidance to $3.3 billion-$3.7 billion, while also increasing Pharma and other growth business profit outlooks. Offsetting the strength were a $184 million Navista goodwill impairment and ongoing tariff uncertainty, but buybacks reached $1 billion year-to-date and leverage improved to 3x.

Analysis

The market should read this as a quality-of-earnings re-rating, not just an earnings beat. The most important signal is that the company is converting operating scale into free cash flow while de-risking the balance sheet, which raises the durability of buybacks and reduces the equity’s discount rate. That combination matters more than the headline EPS step-up because it creates a self-funding compounding loop: higher cash generation supports repurchases, repurchases reduce share count, and lower leverage expands optionality for M&A or further capital returns.

The second-order winner is the specialty-and-services ecosystem around CAH. The company is increasingly acting like a platform rather than a distributor, which should pressure smaller regional distributors and narrower MSO models that cannot cross-sell across pharma, home, nuclear, and logistics. If the Solaris ramp and ADS integration continue to land, the earnings mix shifts toward higher-quality, less commoditized revenue streams; that can compress volatility even if core pharma growth normalizes. The implication for competitors is that price competition becomes harder to use as a weapon because CAH is monetizing adjacency and workflow integration rather than just distribution spread.

The biggest near-term overhang is that a meaningful slice of the current upside is below-the-line: tax, repurchases, and potential tariff refunds. That means the stock can look optically cheap on current-year EPS, but investors will quickly punish any slip in execution or any delay in refund timing because the bridge to the raised guide is partly financial engineering, not purely operating leverage. The contrarian read is that the Navista impairment may actually be a positive signal: management is acknowledging a weaker sub-strategy early and reallocating attention toward the parts of Specialty with better economics. That should be viewed as portfolio pruning, not impairment-driven deterioration, unless the equity/MSO pivot starts to crowd out growth in oncology relationships over the next 2-3 quarters.

Key Decisions for Investors

• Go long CAH on a 3-6 month horizon; thesis is that the market will continue to re-rate the name as a cash compounder with visible buyback support. Best entry is on any post-earnings dip if the stock sells off on the non-cash impairment or tariff timing noise.
• Buy CAH Jan/Apr 2027 call spreads to express upside from Solaris/ADS integration and further specialty mix shift with defined downside. Risk/reward improves if implied volatility stays muted relative to the cash-flow upgrade.
• Pair long CAH / short a basket of smaller medical-distribution or healthcare logistics names that lack scale and cross-sell optionality. The spread should work as CAH’s platform economics and capital returns outperform more fragmented peers over the next 2-4 quarters.
• Avoid chasing on the current EPS beat alone; wait for confirmation that Q4 specialty onboarding and Solaris ramp are translating into FY27 guidance upside before adding aggressively. The key catalyst is guidance, not the quarter.
• For more defensive exposure, consider CAH vs. a broader healthcare services basket as a relative-value long, since CAH’s buybacks and leverage reduction make its equity cash yield more resilient than peers with weaker free-cash-flow conversion.